Eradivir’s EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in […]